References
- Arterberry BJ, Boyd CJ, West BT, Schepis TS, McCabe SE. DSM-5 substance use disorders among college-age young adults in the United States: prevalence, remission and treatment. J Am Coll Health. 2019;1–8.doi:https://doi.org/10.1080/07448481.2019.1590368.
- Pérez-Rojas AE, Lockard AJ, Bartholomew TT, Janis RA, Carney DM, Xiao H, Youn SJ, Scofield BE, Locke BD, Castonguay LG. Presenting concerns in counseling centers: the view from clinicians on the ground. Psychol Serv. 2017;14:416–27.
- Substance abuse and mental health services administration. Nat Surv Drug Use Health. 2019, 2017, 2018.
- Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2017 national survey on drug use and health. HHS Publication No. SMA 18-5068, NSDUH Series H-53. Rockville, MD: Substance Abuse & Mental Health Services Administration; 2018
- Cleveland M, Mallett K, White H, Turrisi R, Favero S. Favero, S. Patterns of alcohol use and related consequences in non-college-attending emerging adults. J Stud Alcohol Drugs. 2013;74:84–93.doi:https://doi.org/10.15288/jsad.2013.74.84.
- Lewis TF, Mobley AK. Substance abuse and dependency risk: the role of peer perceptions, marijuana involvement, and attitudes toward substance use among college students. J Drug Educ. 2010;40:299–314.doi:https://doi.org/10.2190/DE.40.3.f.
- Caldeira KM, Kasperski SJ, Sharma E, Vincent KB, O’grady KE, Wish ED, Arria AM, et al. College students rarely seek help despite serious substance use problems. J Subst Abuse Treat. 2009;37:368–78.
- Sahker E, Acion L, Arndt S. National analysis of differences among substance abuse treatment outcomes: college student and nonstudent emerging adults. J Am Coll Health. 2015;63:118–24.doi:https://doi.org/10.1080/07448481.2014.990970.
- Seth P, Rudd R, Noonan R, Haegrich T. Quantifying the epidemic of prescription opioid overdose deaths. Am J Pub Health Surveillance. 2018;108:500–02.doi:https://doi.org/10.2105/AJPH.2017.304265.
- Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Network Open. 2018;1:e180217.doi:https://doi.org/10.1001/jamanetworkopen.2018.0217.
- Schulenberg J, Johnston L, O’Malley P, Bachman J, Miech R, Patrick M. Monitoring the future, national survey results on drug use, 1975-2018, college students and adults ages 19-50. University of Michigan, Institute for Social Research; 2018.
- Sharma B, Bruner A, Barnett G, Fishman M. Opioid use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25:473–87.doi:https://doi.org/10.1016/j.chc.2016.03.002.
- Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder TIP 63 treatment improvement protocol for healthcare and addiction professionals, policymakers, patients, and families. Rockville, MD: Subtance Abuse & Mental Health Services Administration; 2018.
- Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. J Am Med Assoc. 2017;317:967–68.doi:https://doi.org/10.1001/jama.2017.0001.
- Nielsen S, Larance B, Lintzeris N, Degenhardt L, Gowing L, Kehler C. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Syst Rev. 2016;2016:CD011117.
- National Academies of Sciences, Engineering, and Medicine. Medications for opioid use disorder save lives. Washington D.C.: National Academies of Sciences, Engineering, and Medicine; 2019. Report No.: 9780309486484.
- Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169:137–45.doi:https://doi.org/10.7326/M17-3107.
- MacArthur G, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, Degenhardt L, Hickman M. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.
- DeMaria PA, Sterling RC, Risler R, Frank J. Using buprenorphine to treat opioid-dependent university students: opportunities, successes, and challenges. J Addict Med. 2010;4:236–42.doi:https://doi.org/10.1097/ADM.0b013e3181cf2050.
- Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017;171:747–55.doi:https://doi.org/10.1001/jamapediatrics.2017.0745.
- Feder KA, Krawczyk N, Saloner B. Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder. J Adolesc Health. 2017;60:747–50.doi:https://doi.org/10.1016/j.jadohealth.2016.12.023.
- Kritsonis A. Comparison of Change Theories. Int J Scholarly Acad Intellectual Divers. 2004;8:1.
- Montano D, Kasprzyk D. Theory of reasoned action, theory of planned behavior, and the integrated behavioral model. In: Glanz K, Rimer BK, Viswanath K, editors. Health behavior and health education: theory, research, and practice. San Francisco: Jossey-Bass; 2015. p. 95–124.
- Henshaw EJ, Wall EJ, Lourie AE. How will this help me? Exploring expectations at the time of intake among first-time users of a college counseling center. J Am Coll Health. 2019;1–7.doi:https://doi.org/10.1080/07448481.2019.1624292.
- Saloner B, Feder KA, Krawczyk N. Closing the medication-assisted treatment gap for youth with opioid use disorder. JAMA Pediatr. 2017;171:729–31.doi:https://doi.org/10.1001/jamapediatrics.2017.1269.
- Chouinard S, Prasad A, Brown R. Survey assessing medical student and physician knowledge and attitudes regarding the opioid crisis. WMJ. 2018;117:34–37.
- Countey H, Steinbronn C, Grady SE. Changing student attitudes and perceptions toward opioid use disorder. Mental Health Clin. 2018;8:222–26.doi:https://doi.org/10.9740/mhc.2018.09.222.
- Herbeck DM, Hser YI, Teruya C. Empirically supported substance abuse treatment approaches: A survey of treatment providers’ perspectives and practices. Addict Behav. 2008;33:699–712.doi:https://doi.org/10.1016/j.addbeh.2007.12.003.
- Zylstra RE. The use of spirituality in alcohol recovery. Southern Medical Journal. 2006;99:643.
- Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016;66:48–53.doi:https://doi.org/10.1016/j.jsat.2016.02.009.
- Al-Tayyib AA, Koester S. Injection drug users’ experience with and attitudes toward methadone clinics in Denver, CO. J Subst Abuse Treat. 2011;41:30–36.doi:https://doi.org/10.1016/j.jsat.2011.01.009.
- Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsa N, Monroe CL, O’Grady KE, Olsen YK, Mitchell SG. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addictions. 2013;22:285–91.
- Ridge G, Gossop M, Lintzeris N, Witton J, Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abuse Treat. 2009;37:95–100.doi:https://doi.org/10.1016/j.jsat.2008.09.007.
- Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT Trial:. A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39:340–52.doi:https://doi.org/10.1016/j.jsat.2010.07.009.
- Andraka-Christou B. What is treatment for opioid addiction in problem-solving courts? A study of 20 Indiana drug & veterans courts. Stanford J Civ Rights and Civ Liberties. 2017;13:189–254.
- Andraka-Christou B, Gabriel M, Madeira J, Silverman RD. Court personnel attitudes towards medication-assisted treatment: A state-wide survey. J Subst Abuse Treat. 2019;104:72–82.doi:https://doi.org/10.1016/j.jsat.2019.06.011.
- Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, Marlowe D, Rosenblum A. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44:473–80.
- Conner KO, Rosen D. “You’re nothing but a junkie”: multiple experiences of stigma in an aging methadone maintenance population. J Soc Woik Pracliee Addictions. 2008;8:244–64.
- Lopez G. There’s a highly successful treatment for opioid addiction. But stigma is holding it back. Vox. 2017. p. 1–12.
- Salsitz EA Stigma in methadone and buprenorphine maintenance treatment.
- Hadland SE, Park TW, Bagley SM. Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addict Sci Clin Pract. 2018;13:5.doi:https://doi.org/10.1186/s13722-018-0116-2.
- Andraka-Christou B, Capone MJ. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. Intl J Drug Policy. 2018;54:9–17.doi:https://doi.org/10.1016/j.drugpo.2017.11.021.
- Roose R, Fuentes L, Cheema M. Messages about methadone and buprenorphine in reality television: a content analysis of celebrity rehab with dr. Drew Subst Use & Misuse. 2012;47:1117–24.doi:https://doi.org/10.3109/10826084.2012.680172.
- Rieckmann T, Kovas A, McFarland BH, Abraham AJ. Counselor attitudes toward the use of buprenorphine in substance abuse treatment: a multi-level modeling approach. J Subst Abuse Treat. 2011;41:374–85.doi:https://doi.org/10.1016/j.jsat.2011.05.005.
- Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36:584–89.doi:https://doi.org/10.1016/j.addbeh.2011.01.032.
- Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat. 2007;32:321–29.doi:https://doi.org/10.1016/j.jsat.2006.05.021.
- Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29:95–106.
- McCabe S, Veliz P, Schulenberg J. How collegiate fraternity and sorority involvement relates to substance use during young adulthood and substance use disorders in early midlife: a national longitudinal study. J Adolesc Health. 2018;62:S35–S43.doi:https://doi.org/10.1016/j.jadohealth.2017.09.029.
- Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69:973–81.
- Sullivan MA, Bisaga A, Pavlicova M, Carpenter KM, Choi CJ, Mishlen K, Levin FR, Mariani JJ, Nunes EV. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2018;176:129–37.
- DeLuca JS, Vaccaro J, Seda J, Yanos PT. Political attitudes as predictors of the multiple dimensions of mental health stigma. Int J Soc Psychiatry. 2018;64:459–69.doi:https://doi.org/10.1177/0020764018776335.
- Gonzales L, Chan G, Yanos PT. Individual and neighborhood predictors of mental illness stigma in New York State. Stigma Health. 2017;2:175–81.doi:https://doi.org/10.1037/sah0000043.
- Min JW. The influence of stigma and views on mental health treatment effectiveness on service use by age and ethnicity: evidence from the CDC BRFSS 2007, 2009, and 2012. SAGE Open. 2019;9:3.doi:https://doi.org/10.1177/2158244019876277.
- Schonlau M, Schonlau M, Fricker RD, Fricker RD, Elliott MN, Elliott MN. Conducting research surveys via E-mail and the web. Product page. RAND Corporation. 2002;2002.
- Schulenberg JE, Johnston LD, O’Malley PM, Bachman JG, Miech RA, Patrick ME. Monitoring the future: national survey results on drug use. Volume II, college students and adults ages 19–55. Ann Arbor, MI, 2017; 1975–2016.
- Kosovski J, Smith D. Everybody hurts: addiction, drama, and family in the reality television show intervention. Subst Use Misuse. 2011;46:852–58.doi:https://doi.org/10.3109/10826084.2011.570610.
- Hersey C. Script(ing) treatment: representations of recovery from addiction in hollywood film. Contemp Drug Probl. 2005;32:467–93.doi:https://doi.org/10.1177/009145090503200308.
- Gonzalez JM, Alegrid M, Prihoda TJ. How do attitudes toward mental health treatment vary by age, gender, and ethnicity/race in young adults? J Community Psychol. 2005;33:611–29.doi:https://doi.org/10.1002/jcop.20071.
- Holzinger A, Floris F, Schomerus G, Carta MG, Angermeyer MC. Gender differences in public beliefs and attitudes about mental disorder in western countries: a systematic review of population studies. Epidemiol Psychiatr Sci. 2012;21:73–85.doi:https://doi.org/10.1017/S2045796011000552.
- Santoro T, Santoro J. Racial bias in the us opioid epidemic: a review of the history of systemic bias and implications for care. Cureus. 2018;10:e3733.
- Hansen H, Siegel C, Wanderling J, Dirocco D, Kline N. Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City. Drug and Alcohol Dependence. 2016;164:14–21.
- Hansen H, Skinner ME. From white bullets to black markets to greened medicine: the neuroeconomics and neuroracial politics of opioid pharmaceuticals. Annals of Anthropol Pract. 2012;36:167–82.doi:https://doi.org/10.1111/j.2153-9588.2012.01098.x.
- Andraka-Christou B, Alex B, Lyneé Madeira J. College student preferences for substance use disorder educational videos: a qualitative study. Subst Use Misuse. 2019;54:1400–07.doi:https://doi.org/10.1080/10826084.2019.1581816.
- Kunins HV, Sohler NL, Giovanniello A, Thompson D, Cunningham CO. A buprenorphine education and training program for primary care residents: implementation and evaluation. Subst Abuse. 2013;34:242–47.doi:https://doi.org/10.1080/08897077.2012.752777.
- Chappel J, Veach T. Effect of a course on students’ attitudes toward substance abuse and its treatment. J Med Educ. 1987;62:394–400.doi:https://doi.org/10.1097/00001888-198705000-00004.